UA86059C2 - Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина - Google Patents
Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатинаInfo
- Publication number
- UA86059C2 UA86059C2 UAA200610957A UAA200610957A UA86059C2 UA 86059 C2 UA86059 C2 UA 86059C2 UA A200610957 A UAA200610957 A UA A200610957A UA A200610957 A UAA200610957 A UA A200610957A UA 86059 C2 UA86059 C2 UA 86059C2
- Authority
- UA
- Ukraine
- Prior art keywords
- atorvastatin
- preparation
- tert
- butylester
- polymorphs
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- GCPKKGVOCBYRML-LOYHVIPDSA-N tert-butyl (3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(=O)OC(C)(C)C)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 GCPKKGVOCBYRML-LOYHVIPDSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200400112A SI21745A (sl) | 2004-04-09 | 2004-04-09 | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA86059C2 true UA86059C2 (ru) | 2009-03-25 |
Family
ID=34963800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200610957A UA86059C2 (ru) | 2004-04-09 | 2005-08-04 | Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1732886B1 (e) |
| CN (2) | CN101538238B (e) |
| AT (1) | ATE459602T1 (e) |
| DE (1) | DE602005019703D1 (e) |
| DK (1) | DK1732886T3 (e) |
| EA (1) | EA010166B1 (e) |
| ES (1) | ES2339570T3 (e) |
| HR (1) | HRP20100217T1 (e) |
| NO (1) | NO20065146L (e) |
| PL (1) | PL1732886T3 (e) |
| PT (1) | PT1732886E (e) |
| RS (1) | RS51259B (e) |
| SI (2) | SI21745A (e) |
| UA (1) | UA86059C2 (e) |
| WO (1) | WO2005097742A1 (e) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| US20100260851A1 (en) * | 2007-07-11 | 2010-10-14 | Actavis Group Ptc Ehf | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium |
| WO2009023260A2 (en) * | 2007-08-15 | 2009-02-19 | Teva Pharmaceutical Industries Ltd. | An improved process for synthesis of pyrrole derivative, an intermediate for atorvastatin |
| CN101560177B (zh) * | 2008-04-16 | 2012-10-03 | 北京万全阳光医学技术有限公司 | 一种阿托伐他汀钙的制备方法 |
| SI2413911T1 (sl) | 2009-03-31 | 2014-04-30 | Krka, D.D., Novo Mesto | Progresivna emulzijska kristalizacija |
| CN105693587A (zh) * | 2016-01-15 | 2016-06-22 | 安徽悦康凯悦制药有限公司 | 一种阿托伐他汀钙的生产工艺 |
| CN109280024A (zh) * | 2018-10-09 | 2019-01-29 | 河南师范大学 | 一种高纯度阿托伐他汀叔丁酯的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| EP1341785B1 (en) * | 2000-11-16 | 2008-10-08 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| CN100430405C (zh) * | 2001-08-16 | 2008-11-05 | 特瓦制药工业有限公司 | 制备他汀类的钙盐形式的方法 |
-
2004
- 2004-04-09 SI SI200400112A patent/SI21745A/sl not_active IP Right Cessation
-
2005
- 2005-04-08 AT AT05729986T patent/ATE459602T1/de active
- 2005-04-08 CN CN2009101368132A patent/CN101538238B/zh not_active Expired - Fee Related
- 2005-04-08 CN CN200580012246XA patent/CN1946687B/zh not_active Expired - Fee Related
- 2005-04-08 WO PCT/EP2005/003733 patent/WO2005097742A1/en active Application Filing
- 2005-04-08 EA EA200601651A patent/EA010166B1/ru not_active IP Right Cessation
- 2005-04-08 DE DE602005019703T patent/DE602005019703D1/de not_active Expired - Lifetime
- 2005-04-08 PT PT05729986T patent/PT1732886E/pt unknown
- 2005-04-08 PL PL05729986T patent/PL1732886T3/pl unknown
- 2005-04-08 DK DK05729986.9T patent/DK1732886T3/da active
- 2005-04-08 RS RSP-2010/0173A patent/RS51259B/sr unknown
- 2005-04-08 EP EP05729986A patent/EP1732886B1/en not_active Expired - Lifetime
- 2005-04-08 HR HR20100217T patent/HRP20100217T1/hr unknown
- 2005-04-08 ES ES05729986T patent/ES2339570T3/es not_active Expired - Lifetime
- 2005-04-08 SI SI200531002T patent/SI1732886T1/sl unknown
- 2005-08-04 UA UAA200610957A patent/UA86059C2/ru unknown
-
2006
- 2006-11-08 NO NO20065146A patent/NO20065146L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005019703D1 (de) | 2010-04-15 |
| CN101538238B (zh) | 2012-08-29 |
| EA200601651A1 (ru) | 2007-02-27 |
| RS51259B (sr) | 2010-12-31 |
| ES2339570T3 (es) | 2010-05-21 |
| ATE459602T1 (de) | 2010-03-15 |
| DK1732886T3 (da) | 2010-06-14 |
| HRP20100217T1 (hr) | 2010-05-31 |
| WO2005097742A1 (en) | 2005-10-20 |
| CN1946687A (zh) | 2007-04-11 |
| EA010166B1 (ru) | 2008-06-30 |
| SI1732886T1 (sl) | 2010-06-30 |
| EP1732886A1 (en) | 2006-12-20 |
| PT1732886E (pt) | 2010-03-12 |
| CN1946687B (zh) | 2011-09-28 |
| EP1732886B1 (en) | 2010-03-03 |
| CN101538238A (zh) | 2009-09-23 |
| SI21745A (sl) | 2005-10-31 |
| NO20065146L (no) | 2006-11-08 |
| PL1732886T3 (pl) | 2010-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007058583A3 (en) | Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies | |
| TW200734311A (en) | New compounds | |
| MY147390A (en) | Substituted isoindoles as bace inhibitors and their use | |
| MX2009012168A (es) | Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta. | |
| WO2005062897A3 (en) | Polymorphs of ezetimibe and processes for the preparation thereof | |
| WO2006041405A1 (en) | Substituted amino-pyrimidones and uses thereof | |
| EP1416933B8 (en) | Substituted piperidines as modulators of the melanocortin receptor | |
| WO2003086306A3 (en) | 5ht2c receptor modulators | |
| UY30407A1 (es) | Derivados de [2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-8-il]-fenil sulfonatos sustituidos, composiciones farmacéuticas y aplicaciones. | |
| WO2005070891A3 (en) | Compounds and methods of use | |
| DE60229530D1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
| MX2008008298A (es) | Sal de sulfato de hidrogeno novedosa. | |
| NO20065146L (no) | Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin | |
| MX2008010884A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1. | |
| TNSN07165A1 (en) | Organic compounds | |
| MXPA03012045A (es) | Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico. | |
| WO2008059519A3 (en) | A process for the preparation of intermediates of rosuvastatin | |
| IL183271A0 (en) | Crystalline form of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir | |
| WO2008059513A3 (en) | Compounds suitable as modulators of hdl | |
| WO2007096903A3 (en) | New crystalline form of atorvastatin hemi-calcium | |
| TW200635905A (en) | Processes for producing 4-aminoquinazolines | |
| TW200621223A (en) | Acyclic 1,3-diamines and uses therefor | |
| AU2002356423A1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| WO2006018807A8 (en) | Crystalline forms of cefdinir | |
| GB2434795A (en) | Pyrrolo [2, 1-C] [1, 4] benzodiazepine-anthraquinone conjugates useful as antitumour agents |